On a consolidated basis, Ranix's sales rose from KRW 11 billion in 2022 to KRW 11.5 billion in 2023, the largest year in the 2022 to 2025 period, and then fell 33.2% to KRW 7.71 billion in 2024 and 3.2% to KRW 7.47 billion in 2025.
The operating loss widened every year, from KRW 1.8 billion in 2022 to KRW 2.96 billion in 2023, KRW 5.42 billion in 2024 and KRW 6.05 billion in 2025. The operating margin moved from -16.4% in 2022 to -25.6%, -70.3% and -81.0% in 2025.
In 2024 and 2025 the loss grew faster than sales shrank, which points to a higher fixed-cost burden relative to revenue.
The loss attributable to controlling shareholders grew from KRW 4.93 billion in 2022 to KRW 7.77 billion in 2025, and the net loss including non-controlling interests was also KRW 7.77 billion in 2025.
The debt-to-equity ratio fell from 193.1% in 2022 to 103.9% in 2025, with year-end equity of KRW 21.3 billion and total liabilities of KRW 22.1 billion.
Quarterly sales peaked at KRW 2.11 billion in the third quarter of 2025, fell to KRW 1.79 billion and KRW 1.56 billion, rebounded to KRW 1.94 billion in the second quarter of 2026 (up 23.9% from the prior quarter), and dropped to KRW 1.49 billion in the third quarter (down 23.0% quarter on quarter and 29.3% year on year).
The operating loss was largest at KRW 1.75 billion in the fourth quarter of 2025 and narrowed to KRW 1.57 billion, KRW 1.55 billion and KRW 668 million in the next three quarters.
The narrowing in the third quarter came with lower sales, so whether it reflects cost improvement or timing of spending needs to be separated in the notes to the 2026 annual report.
The controlling-shareholder net loss for the latest four quarters totals KRW 7.11 billion, and operating cash outflows were KRW -5.68 billion in 2024 and KRW -5.12 billion in 2025.